AC187 (TFA) is primarily used in research settings for its role in modulating amylin receptor activity. It acts as a potent and selective antagonist of the amylin receptor, making it a valuable tool in studying metabolic and neurological disorders. Due to its ability to cross the blood-brain barrier, it is frequently employed in neuroscience research, particularly in investigations related to Alzheimer’s disease. Studies suggest that blocking amylin receptors with AC187 (TFA) may help reduce the accumulation of amyloid-beta plaques, a hallmark of Alzheimer’s pathology. It has also been explored for its potential effects on cognitive function and neuroprotection in animal models. Additionally, its specificity makes it useful in receptor binding assays and pharmacokinetic studies focused on central nervous system targets.